How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 195-page report you will receive 33 tables and 61 figures all unavailable elsewhere.
The 195-page report provides clear detailed insight into the neuromodulation devices market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
The revenue of the neuromodulation devices market in 2016 was estimated at $3.77bn and is expected to grow at a CAGR of 11.6% in the first half of the forecast period. The spinal cord stimulation segment accounted for the largest share of the market in 2016, this segment generated $1.89bn.
Read on to discover how this definitive report can transform your own research and save you time.
The new market assessment benefits research, analysis and planning in seven main ways:
• The Neuromodulation Devices Market To 2027 – Discover That Industry’s Overall Sales Potential
• 5 Submarket Revenues To 2027 – Investigate Categories at World Level, Finding the Most Promising Therapies
• 12 National Markets in The Americas, Europe And Asia Covered, With Forecasts To 2027
• Activities of Established, Rising and Emerging Companies – Hear About Firms’ Products, Capabilities, Advances, Collaborations and Outlooks, Mergers and Acquisitions, Research and Development
• Investigate Progress in The Industry, Exploring Technological, Clinical and Commercial Opportunities
• Analysis of What Stimulates and Restrains That Industry and Market – Assess Challenges, Strengths, Competition and Opportunities, Helping You Succeed.
• Discover Neuromodulation Devices Currently in Pipeline and Which Companies Are Active in Clinical Trials for Market Approvals
There you explore business intelligence with research, opinions and predictions found only in that work.
Trying our investigation now lets you discover trends, opportunities and prospects
for neuromodulation devices our report shows you data, trends, opportunities and multilevel sales forecasts.
Report highlights
• 195 pages, 33 tables and 61 figures
• The Neuromodulation Devices Market from 2017 to 2027
• This report also breaks down the revenue forecast for the 6 main submarkets:
• Spinal Cord Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Deep Brain Stimulation
• Gastric Electric Stimulation
• Others – trigeminal nerve stimulation, cochlear implants, transcranial magnetic stimulation, transcranial direct current stimulation and ultrasonic neuromodulation techniques.
• Analysis of key players in Neuromodulation Devices Market:
• Medtronic
• Boston Scientific
• St Jude Medical (Subsidiary of Abbott Diagnostics)
• Cyberonics (Subsidiary of LivaNova)
• Stryker Corporation
• Nevro Corp.
• SetPoint Medical
• Functional Neuromodulation
• Neurotherapies Reset
• Wringless Implantable Stretchable Electronics (WISE)
• Regional the Neuromodulation Devices Market forecasts from 2017-2027
• US forecast 2017-2027,
• China forecast 2017-2027
• Japan forecast 2017-2027
• India forecast 2017-2027
• Germany forecast 2017-2027
• UK forecast 2017-2027
• France forecast 2017-2027
• Italy forecast 2017-2027
• Spain forecast 2017-2027
• Brazil forecast 2017-2027
• Russia forecast 2017-2027
• Key questions answered
• What is neuromodulation? What is the importance of neuromodulation devices, and why are they effective?
• What is the current size of the overall world neuromodulation devices market? How much will this market be worth from 2017 to 2027?
• What are the main drivers and restraints that will shape the overall neuromodulation devices market over the next ten years?
• What are the main segments within the overall neuromodulation devices market? How much will each of these segments be worth during the period 2017-2027? How will the composition of the market change during that time, and why?
• What factors will affect segments of the market over the next ten years?
• What are the largest national markets for neuromodulation devices? What is their current status and how will they develop over the next ten years? What are their sales forecasts for 2017-2027?
• How will political and regulatory factors influence regional markets?
• How will the market shares of the national markets change by 2027 and which geographical region will lead the market in 2027?
• Who are the leading companies for neuromodulation devices and what do they do?
• What are the predictions for existing players and the prospects for new market entrants?
• What are the main trends that will affect the neuromodulation devices market between 2017 and 2027?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that market over the next ten years?
• How will the global neuromodulation devices market evolve over the forecasted period of 2017-2027, including its revenues?
• Target audience
• Leading Hepatitis C companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks
With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the World Market for Neuromodulation Devices
1.2 Why You Should Read This Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.9 About Visiongain
2. Introduction to Neuromodulation
2.1 Neuromodulation
2.2 Techniques Used in Neuromodulation
2.2.1 Electrical Stimulation Techniques
2.2.1.1 Brain and Spinal Cord Therapies
2.2.1.2 Cranial Nerve Stimulation
2.2.1.3 Functional Electrical Stimulation
2.2.2 Pharmacological Therapy
2.3 Application of Neuromodulation
2.3.1 Pain
2.3.2 Depression
2.3.3 Epilepsy
2.3.4 Faecal and Urinary Incontinence
2.3.5 Hearing Disorders – Profound Deafness
2.3.6 Cardiovascular Diseases – Arrhythmia and Angina
2.3.7 Neurodegenerative Diseases – Parkinson’s Disease
3. The Global Neuromodulation Devices Market, 2017-2027
3.1 Global Neuromodulation Devices Market: 2016
3.2 Global Neuromodulation Devices Forecast: 2016-2027
3.3 Neuromodulation Devices: Industry Trends, 2016-2027
3.3.1 Industry Trends - Ageing Population
3.3.2 Rising Prevalence of Chronic Diseases
3.3.3 Industry Trends – Personalised Healthcare
3.3.4 Industry Trends – National Regulations
3.3.5 Political Uncertainty and Security Risk across the World
3.3.6 Industry Trends – Economic Challenges
3.3.7 Industry Trends – Mergers and Acquisitions
4. Spinal Cord Stimulation Submarket, 2017-2027
4.1 Spinal Cord Stimulation (SCS) Market Overview, 2016
4.2 SCS Market Forecast: 2016-2027
4.3 Top Selling & Pipeline SCS Devices, 2017
4.4 Applications of Spinal Cord Stimulation
4.5 SCS Market Trends: 2017-2027
5. Deep Brain Stimulation Submarket, 2017-2027
5.1 Deep Brain Stimulation (DBS) Market Overview, 2016
5.2 DBS Market Forecast: 2016-2027
5.3 Top Selling & Pipeline DBS Devices, 2017
5.4 Applications of Deep Brain Stimulation
5.5 DBS Market Trends: 2017-2027
6. Gastric Electrical Stimulation Submarket, 2017-2027
6.1 Gastric Electrical Stimulation (GES) Market Overview, 2016
6.2 GES Market Forecast: 2016-2027
6.3 Top Selling GES Devices, 2017
6.4 Applications of Gastric Electrical Stimulation
6.5 GES Market Trends: 2017-2027
7. Vagus Nerve Stimulation Submarket, 2017-2027
7.1 Vagus Nerve Stimulation (VNS) Market Overview, 2016
7.2 VNS Market Forecast: 2016-2027
7.3 Top Selling & Pipeline VNS Devices, 2017
7.4 Applications of Vagus Nerve Stimulation
7.5 VNS Market Trends: 2017-2027
8. Sacral Nerve Stimulation Submarket, 2017-2027
8.1 Sacral Nerve Stimulation (SNS) Market Overview, 2016
8.2 SNS Market Forecast: 2016-2027
8.3 Top Selling & Pipeline SNS Devices, 2017
8.4 Applications of Sacral Nerve Stimulation
8.5 SNS Market Trends: 2017-2027
9. Other Neuromodulation Technologies Submarket, 2017-2027
9.1 Other Neuromodulation Technologies Overview, 2016
9.1.1 Trigeminal Nerve Stimulation
9.1.2 Cochlear Implants
9.1.3 Transcranial Magnetic Stimulation (TMS)
9.1.4 Transcranial Direct Current Stimulation (tDCS)
9.1.5 Ultrasonic Neuromodulation
9.2 Other Neuromodulation Techniques Forecast: 2017-2027
10. Neuromodulation Devices in Leading National Developed Markets 2017-2027
10.1 Neuromodulation Devices: Leading Developed Markets, 2016
10.2 The US Neuromodulation Devices Market: 2017-2027
10.2.1 The US Neuromodulation Devices Market: 2016
10.2.2 The US Neuromodulation Devices Market Forecast: 2016-2027
10.3 The Japanese Neuromodulation Devices Market: 2017-2027
10.3.1 The Japanese Neuromodulation Devices Market: 2016
10.3.2 The Japanese Neuromodulation Devices Market Forecast: 2016-2027
10.3.3 The Effects of Regulations on the Japanese Market
10.4 The German Neuromodulation Devices Market: 2017-2027
10.4.1 The German Neuromodulation Devices Market: 2016
10.4.2 The German Neuromodulation Devices Market Forecast: 2016-2027
10.5 The French Neuromodulation Devices Market: 2017-2027
10.5.1 The French Neuromodulation Devices Market: 2016
10.5.2 The French Neuromodulation Devices Market Forecast: 2016-2027
10.5.3 The French Neuromodulation Devices Market – the Economy and its Implications
10.6 The Italian Neuromodulation Devices Market: 2017-2027
10.6.1 The Italian Neuromodulation Devices Market: 2016
10.6.2 The Italian Neuromodulation Devices Market Forecast: 2016-2027
10.6.3 The Italian Neuromodulation Devices Market Outlook
10.7 The UK Neuromodulation Devices Market: 2017-2027
10.7.1 The UK Neuromodulation Devices Market: 2016
10.7.2 The UK Neuromodulation Devices Market Forecast: 2016-2027
10.7.3 The UK Neuromodulation Devices Market Forecast - Political Challenges
10.8 The Spanish Neuromodulation Devices Market: 2017-2027
10.8.1 The Spanish Neuromodulation Devices Market: 2016
10.8.2 The Spanish Neuromodulation Devices Market Forecast: 2016-2027
10.8.3 The Spanish Neuromodulation Devices Outlook
11. Neuromodulation Devices in Leading Emerging Markets 2017-2027
11.1 Neuromodulation Devices: Leading Emerging Markets, 2016
11.2 The Brazilian Neuromodulation Devices Market: 2017-2027
11.2.1 The Brazilian Neuromodulation Devices Market: 2016
11.2.2 The Brazilian Neuromodulation Device Market Forecast: 2016-2027
11.2.3 The Brazilian Neuromodulation Devices Market: Economic and Political Challenges Affecting Prospects
11.3 The Chinese Neuromodulation Devices Market: 2017-2027
11.3.1 The Chinese Neuromodulation Devices Market: 2016
11.3.2 The Chinese Neuromodulation Devices Market Forecast: 2016-2027
11.3.3 The Chinese Neuromodulation Devices Market: Amendments to Regulations.
11.4 The Indian Neuromodulation Devices Market: 2017-2027
11.4.1 The Indian Neuromodulation Devices Market: 2016
11.4.2 The Indian Neuromodulation Devices Market Forecast: 2016-2027
11.5 The Russian Neuromodulation Devices Market: 2017-2027
11.5.1 The Russian Neuromodulation Devices Market: 2016
11.5.2 The Russian Neuromodulation Devices Market Forecast: 2016-2027
12. Neuromodulation Devices Market: Manufacturers
12.1 Medtronic
12.1.1 Sales and Recent Performance Analysis: 2016
12.1.2 Medtronic International Operations
12.1.3 Medtronic-Neuromodulation Performance
12.1.4 Medtronic News
12.1.4.1 Medtronic Mergers
12.1.4.2 Expansion into DBS Market
12.1.4.3 Medtronic Products
12.1.5 Medtronic Market Outlook
12.2 Boston Scientific
12.2.1 Sales and Recent Performance Analysis: 2015
12.2.2 Boston Scientific International Operations
12.2.3 Boston Scientific-Neuromodulation Performance
12.2.4 Boston Scientific News
12.2.4.1 Boston Scientific Acquisitions
12.2.4.2 Expansion into DBS Market
12.2.4.3 Boston Scientific Products
12.2.5 Boston Scientific Market Outlook
12.3 St. Jude Medical (SJM) (now a Abbott company)
12.3.1 Sales and Recent Performance Analysis: 2015
12.3.2 SJM International Operations
12.3.3 SJM-Neuromodulation Performance
12.3.4 SJM News
12.3.4.1 SJM Acquired by Abbott Medical
12.3.4.2 SJM Acquisition
12.3.4.3 SJM Products
12.3.5 SJM - Market Outlook
12.4 Cyberonics (now a LivaNova Company)
12.4.1 Sales and Recent Performance Analysis: 2016
12.4.2 Cyberonics (LivaNova Company) International Operations
12.4.3 Cyberonics (now a LivaNova company) - Neuromodulation Performance
12.4.4 Cyberonics News
12.4.4.1 Cyberonics (LivaNova Company) Investments
12.4.4.2 Cyberonics (LivaNova) Products
12.4.5 Cyberonics (LivaNova) Market Outlook
12.5 Other Companies
12.5.1 Stryker Corporation
12.5.2 Nevro Corp.
12.5.3 SetPoint Medical
12.5.4 Functional Neuromodulation
12.5.5 Neurotherapies Reset
12.5.6 Wiringless Implantable Stretchable Electronics (WISE)
12.5.7 SceneRay
12.5.8 Mindray
13. Qualitative Analysis of the Neuromodulation Devices Market, 2017
13.1 SWOT Analysis of the Neuromodulation Devices Market
13.1.1 Strengths of the Market
13.1.1.1 An Ageing Population
13.1.1.2 Alternative Form of Treatment
13.1.1.3 Convenience
13.1.1.4 Long-term Effectiveness
13.1.2 Weaknesses
13.1.2.1 Research and Development (R&D)
13.1.2.2 Oligarchic Market
13.1.2.3 Adverse Side-Effects of Implantation
13.1.2.4 Shortage of Trained Professionals
13.1.3 Opportunities in the Neuromodulation Devices Market
13.1.3.1 The Advancement of Research
13.1.3.2 A Shift Towards Personalisation
13.1.3.3 Expanding the Target Applications of the Devices
13.1.3.4 Outsource Manufacturing of Devices
13.1.4 Threats Facing the Neuromodulation Devices Market
13.1.4.1 The Challenge of Regulation
13.2 STEP Analysis of the Neuromodulation Devices Market
13.2.1 Social Factors: The Role of Neuroethics
13.2.2 Technological Developments: Drive towards Non-Invasive Methods
13.2.3 Economic Restraints: High Production Costs
13.2.4 Economic Potential: Emerging Markets Create Demand
13.2.5 Political Issues: Strong Government Influence
13.3 Snapshot of Companies in Active Clinical Trials
13.3.1 Neuromodulation Pipeline Products -2016-2017
14. Conclusions
14.1 The United States Retains its Position as Market Leader
14.2 Growing Incidences of Neurological Diseases
14.3 Ageing Population Drives Growth
14.4 China and India will Lead the Emerging Markets
14.5 The Future of the Market - Deep Brain Stimulation and Vagus Nerve Stimulation
14.6 Concluding Remarks
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Appendix B
Visiongain Report Evaluation Form
Table of Tables
Table 1.1 Selected National Neuromodulation Devices Markets: Revenues ($mn) and Market Shares (%) by Leading Country, 2016, 2022 and 2027 (sample table)
Table 3.1 World Neuromodulation Devices Submarkets: Revenue ($mn), AGR (%), CAGRs (%), Market Share (%), 2016-2027
Table 3.2 Global Neuromodulation Devices Markets: Revenue ($mn), AGR (%), CAGR (%), 2016-2027
Table 4.1 SCS Devices Forecast ($mn), AGR (%), Market Share and CAGR (%), 2016-2027
Table 4.2 Leading & Pipeline SCS Devices, 2017
Table 5.1 The DBS Devices Forecast ($mn), AGR (%), Market Share and CAGR (%), 2016-2027
Table 5.2 Leading & Pipeline DBS Devices, 2017
Table 6.1 The GES Devices Forecast ($mn), AGR (%), Market Share and CAGR (%), 2016-2027
Table 6.2 Leading GES Devices, 2017
Table 7.1 The VNS Devices Forecast ($mn), AGR, (%), Market Share and CAGR (%), 2016-2027
Table 7.2 Leading VNS & Pipeline Devices, 2017
Table 8.1 The SNS Devices Forecast ($mn), AGR (%), Market Share and CAGR (%), 2016-2027
Table 8.2 Leading & Pipeline SNS Devices, 2017
Table 9.1 Leading & Pipeline Other Neuromodulation Devices, 2017
Table 9.2 Other Neuromodulation Devices Market: Revenue Forecast ($mn), AGR (%), Market Share and CAGR (%), 2016-2027
Table 10.1 Regional Neuromodulation Devices Markets: Revenue ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 10.2 The US Neuromodulation Devices: Revenue Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 10.3 The Japanese Neuromodulation Devices Revenue Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 10.4 The German Neuromodulation Devices Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 10.5 The French Neuromodulation Devices Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 10.6 The Italian Neuromodulation Devices Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 10.7 The UK Neuromodulation Devices Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 10.8 The Spanish Neuromodulation Devices Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 11.1 Neuromodulation Devices Emerging Markets: Revenue ($bn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 11.2 The Brazilian Neuromodulation Devices Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 11.3 The Chinese Neuromodulation Devices Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 11.4 The Indian Neuromodulation Devices Forecast ($mn), AGR (%) Market Share (%) and CAGR (%), 2016-2027
Table 11.5 The Russian Neuromodulation Devices Forecast ($mn), AGR (%), Market Share (%) and CAGR (%), 2016-2027
Table 12.1 Medtronic Neuromodulation Historical Revenue ($mn), 2014-2016
Table 12.2 Boston Scientific Neuromodulation Historical Revenue ($mn), 2013-2016
Table 12.3 SJM Neuromodulation Historical Revenue ($mn), 2013-2015
Table 12.4 Cyberonics Neuromodulation Historical Revenue ($mn), 2011-2015
Table 13.1 Companies in Active Clinical Trials 2016-2027
Table of Figures
Figure 1.1 Neuromodulation Devices Market Segmentation, 2017
Figure 3.1 Global Neuromodulation Devices Market Share (%) Segmentation, 2016
Figure 3.2 Global Neuromodulation Devices Market: Revenue ($mn), AGR (%), 2016-2027
Figure 3.3 Global Neuromodulation Devices Market Share (%) Segmentation, 2027
Figure 3.4 Global Neuromodulation Devices Market: Drivers and Restraints, 2017-2027
Figure 4.1 SCS Devices Market Share (%) Segmentation, 2016
Figure 4.2 SCS Devices Revenue Forecast ($mn), AGR (%),2016-2027
Figure 5.1 DBS Devices Market Share (%) Segmentation, 2016
Figure 5.2 DBS Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 6.1 GES Devices Market Share (%) Segmentation, 2016
Figure 6.2 GES Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 7.1 VNS Devices Market Share (%) Segmentation, 2016
Figure 7.2 VNS Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 8.1 SNS Devices Market Share (%) Segmentation, 2016
Figure 8.2 SNS Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 9.1 Other Neuromodulation Devices Market Share (%) Segmentation, 2016
Figure 9.2 Other Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2017-2027
Figure 10.1 Regional Neuromodulation Devices Market Shares (%), 2016
Figure 10.2 Regional Neuromodulation Devices Market Shares (%), 2027
Figure 10.3 Developed National Markets: Drivers and Restraints, 2017-2027
Figure 10.4 The US Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2026
Figure 10.5 The Japanese Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 10.6 The German Neuromodulation Devices Market Share (%) within the EU, 2016
Figure 10.7 The German Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 10.8 French Neuromodulation Devices Market Share (%) within the EU, 2016
Figure 10.9 The French Neuromodulation Device Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 10.10 The Italian Neuromodulation Devices Market Share (%) within the EU, 2016
Figure 10.11 The Italian Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 10.12 The UK Neuromodulation Devices Market Share (%) within the EU, 2016
Figure 10.13 The UK Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 10.14 Spanish Neuromodulation Devices Market Share (%) within the EU, 2016
Figure 10.15 Spanish Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 11.1 BRIC Neuromodulation Devices Market Share (%), 2016
Figure 11.2 BRIC Neuromodulation Devices Market Share (%), 2027
Figure 11.3 Emerging National Markets: Drivers and Restraints, 2017-2027
Figure 11.4 Brazilian Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 11.5 Chinese Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 11.6 Indian Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 11.7 Russian Neuromodulation Devices Revenue Forecast ($mn), AGR (%), 2016-2027
Figure 12.1 Medtronic Historical Revenue ($mn), 2012-2016
Figure 12.2 Medtronic Operating Sectors (%), 2016
Figure 12.3 Medtronic Sales Shares (%), 2016
Figure 12.4 Medtronic Neuromodulation Revenue Shares (%) within Restorative Therapies, 2016
Figure 12.5 Medtronic Neuromodulation Historical Revenue ($mn), 2012-2014
Figure 12.6 Boston Scientific Historical Revenue ($mn), 2013-2016
Figure 12.7 Boston Scientific Operating Sectors (%), 2016
Figure 12.8 Boston Scientific Sector Shares (%), 2016
Figure 12.9 Boston Scientific World Sales Shares (%), 2016
Figure 12.10 Boston Scientific Geographical Sales Shares (%), 2016
Figure 12.11 Boston Scientific Neuromodulation Historical Revenue ($mn), 2012-2014
Figure 12.12 Boston Scientific Neuromodulation Revenue Shares (%) within Med-Surgical Sector, 2016
Figure 12.13 St. Jude Medical Revenue ($bn), 2012-2016
Figure 12.14 St. Jude Medical Operating Sectors (%), 2016
Figure 12.15 St. Jude Medical World Sales Shares (%), 2015
Figure 12.16 St. Jude Medical Geographical Sales Shares (%), 2015
Figure 12.17 St. Jude Medical Neuromodulation Revenue ($mn), 2013-2015
Figure 12.18 Cyberonics (LivaNova Company) Historical Revenue ($mn), 2010-2015
Figure 12.19 LivaNova World Sales for Neuromodulation devices Shares (%), April 2015-Dec 2015
Figure 12.20 Nevro Corp. Revenue ($mn), 2015
Figure 13.1 SWOT Analysis of the Neuromodulation Devices Market, 2017
Figure 13.2 STEP Analysis of the Neuromodulation Devices Market, 201
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
